- Mitsubishi Gas Chemical Company (MGC) has signed an agreement with Hokkaido System Science Co. (HSS) to explore entering the nucleic acid drug CDMO business.
- This collaboration aligns with MGC’s “Grow UP 2026” plan, focusing on medical and food sectors.
Mitsubishi Gas Chemical Company has entered a business collaboration with Hokkaido System Science Co. to study the feasibility of developing a nucleic acid drug Contract Development and Manufacturing Organisation (CDMO) business. This partnership is part of MGC’s medium-term management plan, “Grow UP 2026,” which targets the medical and food sectors.
The agreement aims to leverage HSS’s expertise in nucleic acid synthesis and MGC’s capabilities in analytical technology and Good Manufacturing Practice (GMP). Together, they plan to explore the potential for a nucleic acid drug CDMO business to complement MGC’s existing antibody medicine CDMO operations.
The collaboration falls under MGC’s strategy to promote innovative R&D, focusing on building new value through innovation and strengthening the resiliency of its business portfolio. The nucleic acid medicine market is anticipated to have significant growth potential, and this initiative reflects MGC’s commitment to expanding its presence in this field.
“MGC and HSS aim to provide meaningful solutions to stakeholders, including researchers in academia, through this collaboration,” stated a representative from MGC.
 Overview of outsourcing trends 
